- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07697001
Clinical and Neurocomputational Effects of Behavioral Activation in Veterans With Impaired Social Functioning
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Perceived social disconnection and social isolation are disabling and common among Veterans. Yet, these psychosocial impairments can fail to improve following the best available evidence-based treatments. Behavioral activation (BA), an evidence-based treatment for depression has shown promise in improving social functioning. However, most of this research was conducted in primarily non-Veteran populations and has typically relied on patients' subjective symptoms and self-report, in contrast to objective behavioral probes, to assess social functioning. Moreover, the cognitive mechanisms promoting social behavior remain poorly understood, particularly in Veterans. For instance, social anhedonia, i.e., a reduced sensitivity to social rewards, such as positive human interactions, has been implicated as an important driving mechanism of poor social functioning. Yet, the degree to which BA successfully target social reward sensitivity remains unclear and has not been evaluated in Veterans. This lack of understanding limits the ability to develop more targeted and effective interventions for psychosocial recovery. To address these gaps, this study aims to test the clinical and neurobehavioral effectiveness of BA in targeting social dysfunction in Veterans.
Computational models of reward learning (RL), particularly Bayesian RL learning models, can offer an important bridge to link in-vivo behavior, such as social reward sensitivity, and recovery outcomes like psychosocial functioning, by providing a rich quantitative representation of reward learning and its dynamic updating during reward exploration. This proposal aims to capitalize on this approach, combining a translational behavioral paradigm, Bayesian reinforcement learning modeling, and neuroscientific evaluation of change processes, in order to assay social anhedonia and improve prediction of social functioning as well as understanding and effective dissemination of BA treatment.
The specific aims are to: 1) test the effectiveness of BA in improving social functioning outcomes in Veterans (Aim 1); 2) examine the impact of BA on neurocomputational markers of social reward sensitivity and their relationship to social functioning improvement in Veterans (Aim 2); and 3) assess the degree to which neurocomputational markers of social reward sensitivity predict social functioning recovery in Veterans undergoing BA (Aim 3). This project will also explore whether the relationships between neurocomputational markers of social function and clinical outcomes are moderated by primary diagnosis (exploratory Aim 4).
Veterans (N=136) with impaired social functioning and anhedonia will be recruited and randomized to either behavioral activation (BA) or supportive care therapy (SCT; active control) over 12 weeks. At baseline, immediately post-treatment, and 12-weeks post-treatment (24-weeks follow-up), participants will complete a computerized task aimed at probing social reward-seeking behavior, in which they must choose between unknown partners with the goal of maximizing the number of compliments they receive from these partners. Concurrent brain activity will be collected with functional magnetic resonance imaging (fMRI) in a subset of participants (N=68; at baseline and post-treatment). Therapy sessions and follow-up (24-weeks) assessments will be administered through VA-approved telehealth methods. Computational modeling will be used to derive individual parameters of social reward (i.e., compliments) learning and maximization, and to extract associated neural activity, e.g., neural responses to prediction error signals (discrepancies between expected and actually obtained reward/compliment). Randomization of participants to treatment arms will be be stratified based on fMRI eligibility status, sex, and primary psychiatric diagnosis.
This project is expected to 1) determine if BA offers an effective, low-burden option to improve social functioning in Veterans; 2) identify potential neurocognitive targets, which could be used in future research to develop and test novel treatments to improve psychosocial functioning in Veterans, such as computerized neurocomputational training protocols to boost social reward sensitivity; and 3) help identify precise markers of BA responsiveness for functional recovery.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Niloofar Afari, PhD
- Telefonnummer: (858) 642-3657
- E-mail: Niloofar.Afari@va.gov
Studiesteder
-
-
California
-
San Diego, California, Forenede Stater, 92161-0002
- VA San Diego Healthcare System, San Diego, CA
-
Kontakt:
- Niloofar Afari, PhD
- Telefonnummer: 858-642-3657
- E-mail: Niloofar.Afari@va.gov
-
Ledende efterforsker:
- Katia Harle, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- being a Veteran
- having moderate to high levels of social disconnection (Social Connectedness Scale-Revised/SCS-R score < 90)
- having moderate to high levels of social functioning impairments (Sheehan Disability Scale/SDS-social domain score >=5)
- having moderate to high levels of social anhedonia (Specific Loss of Interest and Pleasure Scale/SLIPS score >= 6)
Exclusion Criteria:
- lifetime history of psychotic or bipolar disorder
- neurological conditions, neurodevelopmental disorders, or sensory deficits that may impact cognitive functioning to preclude understanding/completion of study procedure
- regular use of certain psychotropic medications that may significantly impact goal-directed performance on the task (i.e., benzodiazepines, sedative hypnotics, and opioid analgesics); pre-existing stable doses of psychotropic medications, such as SSRIs, will be allowed (if same regimen has been taken for at least 30 days)
- current severe alcohol or substance use disorders (AUD/SUD) necessitating prioritization of substance use treatment
- suicidal or homicidal ideation within the past month necessitating urgent higher-level care
- concurrent individual cognitive-behavioral psychotherapy specifically targeting depression, anhedonia, and/or PTSD
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Behavioral Activation (BA)
This arm provides the experimental treatment, i.e., Behavioral Activation therapy.
|
BA is a structured behavioral protocol for depression, designed to help individuals increase engagement in meaningful and rewarding activities, thereby breaking the cycle of avoidance and inactivity that often accompanies depression.
The protocol teaches patients to increase a) engagement in pleasant, reinforcing activities, with a strong emphasis on social engagement and social connection, b) exploration of values, and c) goal-setting and goal-directed behavior, while monitoring their mood and daily activities
|
|
Aktiv komparator: Supportive Care Therapy (SCT)
This arm provides the active control treatment, i.e., Supportive Care Therapy.
|
SCT is a Rogerian non-directive approach and employs techniques to convey a deep understanding of emotions, thoughts, and behaviors of the Veterans receiving this treatment.
Specific techniques include content-focused paraphrasing, exploration through open-ended questions (with a goal of empathic understanding), and emotion-focused reflection and validation.
Consistent with the SCT model, the therapist will be explicitly instructed not to provide advice, assign activities, or suggest strategies and techniques employed in the BA intervention.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Social Connectedness Scale - Revised (SCS-R)
Tidsramme: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
Measures the degree to which individuals feel connected to others in their social environment.
Scores range from 20 to 120, where higher scores indicate a stronger, healthier sense of social connectedness.
|
Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
|
Inventory of Psychosocial Functioning (IPF)
Tidsramme: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
The scale measures the degree of impairment in ability to interact effectively with others, fulfill social roles (e.g., work), and meet personal and societal expectations.
It is comprised of 7 subscales.
Each item ranges from 0 to 6. Higher scores indicate greater degree of impairment in psychosocial functioning.
|
Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
|
Specific Loss of Interest and Pleasure Scale (SLIPS)
Tidsramme: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
This is a measure of social anhedonia, i.e., hypo-responsiveness to social rewards, such as positive human interactions.
Scores range from 0 to 69.
Higher scores indicate greater severity of social anhedonia.
|
Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
|
Social Reward Maximization
Tidsramme: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
Computational parameter derived from behavioral social functioning probe (behavioral reinforcement learning task), capturing the degree to which individuals select social partners they predict to be more rewarding (to offer the most compliments).
|
Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
|
Neural Activation to Social Reward Prediction Errors (RPEs)
Tidsramme: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
Average BOLD (Blood-Oxygenation-Level Dependent) % signal change (i.e., activation) associated with individuals' model-based RPE (difference between expected probability of reward/compliment and actual outcome received.
i.e., compliment vs no-compliment).
|
Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Primary Psychiatric Diagnosis
Tidsramme: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
Primary diagnostic category (i.e., depressive vs traumatic stress/anxiety disorder)
|
Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
|
World Health Organization Quality of Life Scale (WHOQOL-BREF)
Tidsramme: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
Measures quality of life and life satisfaction.
Includes 4 domain subscales: physical health (range 7-35), psychological health (range 6-30), social relationships (range 3-15), and environment (range 8-42).
Higher scores indicate higher quality of life.
|
Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
|
Patient Health Questionnaire-9 (PHQ-9)
Tidsramme: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
Measures depression severity.
Scores range from 0 to 27.
Higher scores indicate greater depression severity.
|
Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
|
PTSD Checklist-5 (PCL-5)
Tidsramme: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
Measures post-traumatic stress disorder (PTSD) severity.
Scores range from 0 to 80, with higher scores indicating greater PTSD severity.
|
Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
|
Beck Anxiety Inventory (BAI)
Tidsramme: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
This scale measures anxiety severity.
Scores range from 0 to 63, with higher scores indicating greater anxiety severity.
|
Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
|
Snaith-Hamilton Pleasure Scale (SHAPS)
Tidsramme: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
Measure of anhedonia.
Score range from 14 to 56, with higher scores indicating greater anhedonia severity.
|
Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Reaction to Treatment Questionnaire
Tidsramme: Baseline, Post-Treatment (12-weeks)
|
Measure of treatment satisfaction and credibility of treatment rationale.
Total scores range from 3 to 27, with higher scores indicating greater satisfaction and credibility in the treatment.
|
Baseline, Post-Treatment (12-weeks)
|
|
Mood and Anxiety Symptoms Questionnaire (MASQ-D30)
Tidsramme: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
Measure of anhedonic depression, anxiety, and stress symptoms.
The scale has three subscales (general distress, anhedonic depression, and anxious arousal) , with each score ranging from 10 to 50.
Higher scores indicate greater severity of symptoms.
|
Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
|
Liebowitz Social Anxiety Scale (LSAS)
Tidsramme: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
Assesses the impact of social anxiety on multiple aspects of life.
Scores range from 0 to 144, with higher scores indicating greater social anxiety.
|
Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Katia Harle, MD, VA San Diego Healthcare System, San Diego, CA
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neurologiske manifestationer
- Sygdomme i nervesystemet
- Neuroadfærdsmæssige manifestationer
- Patologiske tilstande, tegn og symptomer
- Opførsel
- Tegn og symptomer
- Social adfærd
- Anhedonia
- Social tilpasning
- Terapeutik
- Patientpleje
- Sundhedstjenester
- Sundhedsfaciliteter Arbejdsstyrke og tjenester
- Palliativ pleje
Andre undersøgelses-id-numre
- RRD4-009-25W
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
One or more data sets without personal identifiers will be generated during the data analysis phase of this study. The data sets will include all data underlying any publications generated by this study as well as statistical code, and therefore these will be sufficient to reproduce or verify any published findings.
Any HIPAA identifiers, or combinations of variables that could be used for re-identification, will be excluded, as will any proprietary information. The plan does not include any access to individually identifiable or proprietary data. Therefore, this plan will ensure the protection of personal privacy, the confidentiality of individually identifiable private information, and the security of proprietary data and information.
IPD-delingstidsramme
IPD-delingsadgangskriterier
IPD-deling Understøttende informationstype
- ANALYTIC_CODE
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Social Anhedonia
-
Maastricht UniversityAristotle University Of Thessaloniki; P1vital Products LTD.; Biotrial; University... og andre samarbejdspartnereAfsluttetDepression | Skizofreni | Motivering | Anhedonia, fysisk | Anhedonia, Social | Negative symptomer med primær psykotisk lidelseTyskland, Grækenland, Holland, Spanien
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)RekrutteringAnhedonia | Fobiske lidelser | Social angst (social fobi) | ANGSTFORSTYRELSER (eller angst og fobiske neuroser) | Offentlig taleangstForenede Stater
-
CEN BiotechCEN Nutriment; Biovet Conseil; Amadeite SASAfsluttet
-
German University of Health and SportsAfsluttet
-
Virginia Commonwealth UniversityNational Center for Advancing Translational Sciences (NCATS)AfsluttetPsykologi, Social | Social interaktion | Interpersonelle relationer | Adfærd, SocialForenede Stater
-
Centre Hospitalier Universitaire de NiceAfsluttet
-
University of Maryland, College ParkEunice Kennedy Shriver National Institute of Child Health and Human Development...AfsluttetPeer gruppe | Social udstødelse | Fordomme, race | Fordomme | SexismeForenede Stater
-
VA Office of Research and DevelopmentRekruttering
-
University of British ColumbiaVancouver Foundation; Inner-City Women's Initiatives SocietyAfsluttetEnsomhed | Social støtte | Social isolationCanada
-
Aya Technologies LimitedAfsluttetSocial angst | Social angst | Social angst (social fobi)Det Forenede Kongerige
Kliniske forsøg med Behavioral Activation (BA)
-
Lovisenberg Diakonale HospitalOslo Metropolitan UniversityAfsluttet
-
Truway Health, Inc.Tilmelding efter invitationStillesiddende adfærd | Sundhedsadfærd | AdfærdsaktiveringForenede Stater
-
Boston UniversityUkendtDepressionForenede Stater
-
Indiana UniversityAfsluttet
-
University of OviedoAfsluttet
-
Pakistan Institute of Living and LearningFatima Jinnah Women UniversityIkke rekrutterer endnu
-
Mount Sinai Hospital, CanadaHarvard Medical School (HMS and HSDM); Patient-Centered Outcomes Research... og andre samarbejdspartnereAfsluttetPerinatal depressionForenede Stater, Canada
-
University of PittsburghThe Klingenstein Third Generation FoundationAfsluttetDepression i ungdomsårene | Uønskede barndomsoplevelserForenede Stater
-
The Royal's Institute of Mental Health ResearchAfsluttetManiodepressiv | Depressiv lidelse, major | Depressiv lidelse, behandlingsresistentCanada
-
VA Office of Research and DevelopmentRekrutteringDepression | Hjerte-kar-sygdommeForenede Stater